[1]张祥,阚全程#,余祖江,等.PreSTat真核表达载体的构建及表达*[J].郑州大学学报(医学版),2011,(05):706-60.
 ZHANG Xiang,KAN Quancheng,YU Zujiang,et al.Construction and expression of eukaryotic vector encoding PreSTat[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(05):706-60.
点击复制

PreSTat真核表达载体的构建及表达*
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2011年05期
页码:
706-60
栏目:
论著
出版日期:
2011-09-20

文章信息/Info

Title:
Construction and expression of eukaryotic vector encoding PreSTat
作者:
张祥1阚全程1#余祖江2王鹏3
1)郑州大学第一附属医院药学部 郑州 450052 2)郑州大学第一附属医院感染科 郑州450052 3)郑州大学护理学院 郑州450001
Author(s):
ZHANG Xiang1KAN Quancheng1YU Zujiang2WANG Peng3
1)Department of Pharmacy, the First Affiliated Hospital,Zhengzhou University, Zhengzhou 450052 2)Department of Infectious Diseases, the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052 3)College of Nursing,Zhengzhou University,Zhengzhou 450001
关键词:
PreSTat乙型肝炎病毒蛋白转导区
Keywords:
PreSTathepatitis B virusprotein transduction domain
分类号:
Q784
摘要:
目的:构建pEGFPPreSTat嵌合载体并在真核细胞中表达。方法:提取人乙型肝炎病毒并用PCR法扩增出PreS片段,定向克隆入pEGFPC3载体,在PreS下游连接合成的Tat序列,构建成功的pEGFPPreSTat质粒经脂质体转染Hela细胞,Western blot鉴定目的蛋白的表达。结果:酶切和测序结果表明成功地构建了pEGFPPreSTat嵌合载体,Western Blot结果表明该载体能在Hela细胞中表达pEGFPPreSTat融合蛋白。结论:成功构建pEGFPPreSTat载体并表达出相应的融合蛋白,为研究该融合蛋白的功能奠定了基础。
Abstract:
Aim:To construct the chimeric vector PreSTat and express it in the eukaryotic cells.Methods:After amplifying the HBV PreS gene, the products were cloned into the pEGFPC3 vector. The synthetic Tat sequences were inserted into the downstream of the PreS.The resultant recombinant vectors were transfected into eukaryotic cell Hela by lipofectamine. Western blot was used to certify the purpose protein.Results:The recombinant plasmid was confirmed by restriction endonuclease and sequencing. The pEGFPPreSTat fusion protein was successfully expressed in the Hela cells.Conclusion:pEGFPPreSTat has been constructed and the fusion protein is expressed successfully,which lays the foundation for studying the functions of the protein.

参考文献/References:

[1]Loomba R,Liang TJ. Novel approaches to new therapies for hepatitis B virus infection[J].Antivir Ther,2006,11(1):1
[2]Lavanchy D.Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures[J].J Viral Hepat,2004,11(2):97
[3]Lin Y, Liu YX, Cislo T,et al.Expression and characterization of the preS1 peptide of hepatitis B surface antigen in Escherichia coli[J].J Med Virol,1991,33(3):181
[4]Tang KH,Yusoff K,Tan WS.Display of hepatitis B virus PreS1 peptide on bacteriophage T7 and its potential in gene delivery into HepG2 cells[J].J Virol Methods,2009,159(2):194
[5]Miyata R,Ueda M,Jinno H,et al.Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholinebased amphiphilic block copolymer micelles as a biocompatible, drug delivery carrier for treatment of human hepatocellular carcinoma with paclitaxel[J].Int J Cancer,2009,124(10):2460
[6]Oess S,Hildt E. Novel cell permeable motif derived from the PreS2domain of hepatitisB virus surface antigens[J]. Gene Ther, 2000,7(9):750
[7]Yamauchi K,Nakamura T,Yonemitsu H,et al.Possible role of preS2 peptides presented by MHC class Ⅰantigen in the pathogenesis of chronic hepatitis B[J].J Hepatol, 1993,17(Suppl 3):S6
[8]Madalinski K,Sylvan SP,Hellstrom U,et al.Presence of antipreS1, antipreS2, and antiHBs antibodies in newborns immunized with BioHepB vaccine[J]. Med Sci Monit,2004,10(1):P110
[9]Eum WS,Choung IS, Li MZ,et al. HIV1 Tatmediated protein transduction of Cu,Znsuperoxide dismutase into pancreatic beta cells in vitro and in vivo[J]. Free Radic Biol Med, 2004,37(3):339

相似文献/References:

[1]王茜茜),宋波),苗成),等.TATSOD融合蛋白表达载体的构建*[J].郑州大学学报(医学版),2010,(01):72.
 WANG Qianqian),SONG Bo),MIAO Cheng),et al.Construction of TATSOD fusion protein expression vector[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(05):72.

备注/Memo

备注/Memo:
*国家自然科学基金资助项目30472031 #通讯作者,男,1963年9月生,博士,教授,主任药师,研究方向:免疫药理,Email:sennheiser163@163.com
更新日期/Last Update: 2011-09-20